MEET QPS AT THE WORLDSymposium™ 2024; February 4 - 9, SAN DIEGO, CALIFORNIA, USA

Aβ Peptide Formation or Screening for Secretase Inhibitors

Aβ Peptide Formation or Screening for Secretase Inhibitors

Generation of Aβ species is a hallmark of Alzheimer’s Disease. QPS Neuropharmacology provides several cell culture models to identify pharmacological agents that interfere with the cleavage of APP by analyzing the generation of different Aβ and sAPP species by immunosorbent assay.

  • H4 neuroglioma cells overexpressing human APPK595N/M596L, the Swedish double mutation, enable to analyze compounds for their effects on the human mutant APP profile.
  • Primary rat/mouse hippocampal neurons are phenotypically closer to adult neurons as they present an extended dense network of neuronal processes.
  • Primary chicken telencephalic neurons secrete endogenous wild type Aβ peptides, including Aβ38, Aβ40 and Aβ42. Both human and chicken Aβ42 are identical in sequence. Therefore, this model is suitable for studying effects on processing of endogenous wild type APP in primary neurons.
H4 cells

Figure: Aβ peptide secretion in APPK595N/M596L overexpressing cells.

H4 cells overexpressing human APPK595N/M596L secrete high levels of Aβ1-42 (A) and Aβ1-40 (B) determined by an immunosorbent assay. The γ-secretase inhibitor DAPT reduces Aβ formation in H4-hAPPK595N/M596L cells and affects the Aβ42 to 40 ratio (C) . Two concentrations of a developmental compound were also able to reduce Aβ secretion in a dose dependent manner. Mean + SEM; One-way ANOVA with Bonferroni‘s post hoc test; **p<0.01, ***p<0.001.

Czvitkovich et al, J Mol Neurosci. 2011; 43(3): 257–267.

In Vitro Services

QPS Neuropharmacology provides research services with numerous standardized cell culture systems including transgenic and non-transgenic cell lines, glial cells, primary chicken and rat peripheral and central nervous system neurons of different developmental stages and organotypic brain slices. New models are developed and validated on request.
LEARN MORE

In Vivo Services

As a leading CRO for CNS drug development, QPS Neuropharmacology is the premier provider for services with transgenic animals. We have more than 20 years of experience in generating, characterizing, and maintaining transgenic disease models and applying them for drug testing projects.
LEARN MORE

Ex Vivo Services

QPS Neuropharmacology's expertise lies within the field of neurodegenerative diseases. We provide a state of the art research environment (AAALAC certified) for testing and evaluating new potential treatment approaches.
LEARN MORE

Biobank

QPS Neuropharmacology's well characterized and validated in vivo models are useful tools to push your CNS drug discovery research forward. We are happy to support your research activities with sample material from our biobank composed of various specimen derived from our in-house in vivo models.
LEARN MORE

animal models

QPS Neuropharmacology is highly experienced in generating, characterizing, and maintaining transgenic disease models and using them for drug testing projects for more than 20 years.
LEARN MORE

behavioral testing

QPS Neuropharmacology provides a wide range of behavioral tests for various indications. Most tests are evaluated using rater-independent digital animal tracking systems.
LEARN MORE

histology services

QPS Neuropharmacology offers a full set of histology services ranging from collection of tissue samples to delivering study reports that contain all experimental procedures and their outcome.
LEARN MORE

biomarkers

QPS Neuropharmacology Department of Translational Medicine offers a selection of molecular biological methods for the investigation of various diseases. The unit supports in vitro and in vivo studies performed at QPS Austria.
LEARN MORE